We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

49 hedge funds and large institutions have $30.2M invested in Axsome Therapeutics in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

20% more funds holding

Funds holding: 41 → 49 (+8)

1.66% more ownership

Funds ownership: 32.21% → 33.86% (+1.7%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

27% less capital invested

Capital invested by funds: $41.6M → $30.2M (-$11.4M)

Holders
49
Holders Change
+8
Holders Change %
+19.51%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
12
Reduced
12
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RA
Royce & Associates
New York
+$4.21M
2
BlackRock
BlackRock
New York
+$2.35M
3
SFM
Sphera Funds Management
Israel
+$1.92M
4
NC
Nexthera Capital
New York
+$1.91M
5
OPPM
Opus Point Partners Management
New York
+$1.28M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.7M
2
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.69M
3
Morgan Stanley
Morgan Stanley
New York
-$157K
4
JP Morgan Chase
JP Morgan Chase
New York
-$39.9K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$39.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$7.01M -$2.7M -565,213 -24%
JP Morgan Chase
2
JP Morgan Chase
New York
$6.22M -$39.9K -8,340 -0.5%
RA
3
Royce & Associates
New York
$3.44M +$4.21M +881,000 New
BlackRock
4
BlackRock
New York
$1.92M +$2.35M +491,086 +117,204%
Stifel Financial
5
Stifel Financial
Missouri
$1.62M – – –
SFM
6
Sphera Funds Management
Israel
$1.56M +$1.92M +401,000 New
NC
7
Nexthera Capital
New York
$1.56M +$1.91M +400,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.3M +$299K +62,556 +23%
OPPM
9
Opus Point Partners Management
New York
$1.04M +$1.28M +267,000 New
SCM
10
Sio Capital Management
New York
$819K +$1M +210,000 New
State Street
11
State Street
Massachusetts
$540K +$16.7K +3,500 +3%
Allianz Asset Management
12
Allianz Asset Management
Germany
$500K +$86.5K +18,110 +16%
Northern Trust
13
Northern Trust
Illinois
$437K +$33.3K +6,966 +7%
Millennium Management
14
Millennium Management
New York
$316K -$18.3K -3,829 -5%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$225K +$24.6K +5,156 +10%
DCM
16
DAFNA Capital Management
California
$217K +$266K +55,700 New
Mariner
17
Mariner
Kansas
$179K +$4.78K +1,000 +2%
SG Americas Securities
18
SG Americas Securities
New York
$139K +$171K +35,734 New
TCIM
19
TIAA CREF Investment Management
New York
$124K -$19.4K -4,050 -11%
Goldman Sachs
20
Goldman Sachs
New York
$121K +$148K +30,920 New
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$102K +$15.8K +3,300 +14%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$88K -$39.2K -8,195 -27%
PAM
23
PVG Asset Management
Colorado
$80.3K +$98.4K +20,595 New
BWP
24
Baldwin Wealth Partners
Massachusetts
$77K – – –
Charles Schwab
25
Charles Schwab
California
$70K – – –
1
2

AXSM Hedge Fund Activity: Q1 2017 in Review

49 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2017, worth a combined $30.2M — down 27% from $41.6M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AXSM positions and 1 closed out — a net gain of 12 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $4.21M. The largest seller was Fidelity Investments, cutting an estimated $2.7M.

  • 49 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2017, up from 41 in Q4 2016.
  • Funds reported $30.2M of Axsome Therapeutics stock for Q1 2017, down 27% quarter-over-quarter.
  • 13 funds opened new Axsome Therapeutics positions in Q1 2017 and 1 closed out, a net change of +12 holders.
  • The largest Axsome Therapeutics buyer in Q1 2017 was Royce & Associates, an estimated $4.21M added.
  • The largest Axsome Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $2.7M sold.

Based on aggregated 13F filings for Q1 2017.